Stock Ratings / Health Care / LFCR / earnings

ELDN (39) EVMN (31) VNDA (20) CAMP (25) ⌘ Pro Terminal →

Lifecore Biomedical Inc. (LFCR) Next Earnings Date & Expected ±1.9% Move

$6.52 +0.15% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.51

Lifecore Biomedical Inc. (LFCR) carries a Roarable Rating of D+ (Sell) with 57/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 57/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.2% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $246.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LFCR Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LFCR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Lifecore Biomedical Inc. (NASDAQ: LFCR) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $6.52 (+0.15% 1D, market cap $246.8M). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, LFCR ranks #210 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LFCR compare to ELDN and EVMN in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LFCR carries a Roarable D+ (57/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ELDN (Eledon Pharmaceuticals Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $247.0M) and EVMN (Evommune Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $247.1M). Among the 5-stock peer group, LFCR leads on earnings multiple (N/A) while ELDN leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LFCR?

▼

Per LFCR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001005286), Lifecore Biomedical Inc. generated $0 in revenue (-100.0% YoY), $0 in net income, and $0 in free cash flow against $232.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $6.51 (-0.16%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 11/20 (D+) • 0.2% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 57/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.2% avg 90D alpha vs SPY • 52.2% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE-0.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LFCR)Realized 20D OHLCV Swing Band: ±1.9%

Deterministic 5-Pillar Attribution (57/100 Composite)

🔍 WHY LFCR SCORES 57/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+13/20 pts (23% of score)

20D Institutional Volume Accumulation (±1.9% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (23% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$6.44-0.8% Next Q

Q2 (-2Q)

Grade C-$6.39+0.8% Next Q

Q3 (-1Q)

Grade C-$6.44+1.2% Next Q

Current

Grade D+$6.52-0.2% Hist 90D α

Trajectory: D (49) → D+ (57)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the LFCR Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 57/100 (D+) score, LFCR faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($5.46) or 200D SMA ($5.50) invalidates the momentum regime and cuts Target Base ($6.49) toward Bear Floor ($5.06).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LFCR• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “LFCR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 57%NO 43%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±1.9% Swing Band

±$0.12 Expected Swing

MODEL EARNINGS SETUP GAUGE

LFCR Quantitative Pre-Earnings Setup: 57/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (57/100)Model Risk Weight (43/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$0	$0	$0	52%
FY 2024	2025-05-25	$128.9M	-$38.7M	-$13.6M	31.3%
FY 2023	2024-05-26	$0	$12.0M	$257.0K	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LFCR)

✓Walkthrough of LFCR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LFCR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +27.10%📐 HORIZONTAL RANGE

2026-11-02O $6.51H $6.52L $6.51C $6.52VOL 240.9K

RES: $7.32SUP: $3.90SMA50: $5.46SMA200: $5.50

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LFCR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LFCR Butterfly Map → + Track LFCR →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LFCR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LFCR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LFCR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LFCR)

Health Care Rank #210 of 1016 ⚔️ ELDN vs LFCR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LFCR vs. ELDN, EVMN, VNDA, CAMP)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Lifecore Biomedical Inc. (LFCR) ranks #210 by composite RQD confidence (57/100, grade D+) and #550 by equity capitalization ($246.8M). Within this direct 5-issuer industry benchmark cohort, LFCR leads on earnings valuation at N/A trailing P/E, while ELDN leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. LFCR currently leads its immediate peer cohort in composite quantitative strength at 57/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LFCR ACTIVE Lifecore Biomedical Inc.	D+	57/100	—	—	—	+0.15%	$246.8M	Benchmark Subject
ELDN Eledon Pharmaceuticals Inc.	D-	39/100	—	—	-35.0%	+10.15%	$247.0M	/eldn-vs-lfcr →
EVMN Evommune Inc.	E	31/100	—	—	-35.0%	+7.92%	$247.1M	/evmn-vs-lfcr →
VNDA Vanda Pharmaceuticals Inc.	E	20/100	—	—	-35.0%	+1.25%	$244.9M	/vnda-vs-lfcr →
CAMP CAMP4 Therapeutics Corporation	E	25/100	—	—	-35.0%	+6.85%	$244.7M	/camp-vs-lfcr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001005286

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Lifecore Biomedical Inc. (LFCR) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $128.9M ) , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, LFCR closed FY2025 with $232.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$0	—	—	$232.2M	—
FY2024 (FY)	2025-05-25	$128.9M	-$38.7M	-$206.0K	-$13.6M	$255.4M	$110.5M
FY2023 (FY)	2024-05-26	$0	$12.0M	$257.0K	$257.0K	—	—

3. LFCR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LFCR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does LFCR compare to ELDN and EVMN in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for LFCR?

Where is LFCR trading relative to its 50-day, 200-day, and 52-week technical levels?

LFCR last traded at $6.52 (+0.15% on volume of 240,912 shares), positioning the stock +19.41% above its 50-day simple moving average ($5.46) and +18.55% above its 200-day simple moving average ($5.50). Across its 52-week range of $3.63 to $8.98, LFCR sits at the 54.0% percentile with a 14-day RSI of 69.5 (BULLISH MOMENTUM) and an implied next-earnings move of ±1.9% ($6.40 to $6.64).